Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have completed the study treatment and visit schedule through Week 96 in Study 105MS301 (NCT00906399).~Key Exclusion Criteria:~* Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study 105MS301 (NCT00906399).~* Subjects with any clinically significant laboratory abnormalities, malignancies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease~* Pregnant or nursing women.~NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- peginterferon beta-1a Q4W (Type: EXPERIMENTAL): 125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
- peginterferon beta-1a Q2W (Type: EXPERIMENTAL): 125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).